Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Solid Biosciences (SLDB) Equity Average (2018 - 2024)

Solid Biosciences' Equity Average history spans 7 years, with the latest figure at $180.1 million for Q3 2024.

  • For Q3 2024, Equity Average rose 16.94% year-over-year to $180.1 million; the TTM value through Sep 2024 reached $180.1 million, up 16.94%, while the annual FY2023 figure was $169.1 million, 19.47% down from the prior year.
  • Equity Average for Q3 2024 was $180.1 million at Solid Biosciences, down from $202.0 million in the prior quarter.
  • Across five years, Equity Average topped out at $245.5 million in Q2 2021 and bottomed at $31.5 million in Q3 2020.
  • The 5-year median for Equity Average is $173.9 million (2022), against an average of $159.1 million.
  • The largest annual shift saw Equity Average tumbled 65.98% in 2020 before it skyrocketed 632.88% in 2021.
  • A 5-year view of Equity Average shows it stood at $77.2 million in 2020, then surged by 179.67% to $215.8 million in 2021, then decreased by 17.76% to $177.5 million in 2022, then fell by 23.69% to $135.4 million in 2023, then surged by 33.02% to $180.1 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Equity Average are $180.1 million (Q3 2024), $202.0 million (Q2 2024), and $168.6 million (Q1 2024).